These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 19330726

  • 1. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE.
    Curr Opin Mol Ther; 2009 Apr; 11(2):208-18. PubMed ID: 19330726
    [Abstract] [Full Text] [Related]

  • 2. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.
    J Mol Biol; 2007 May 04; 368(3):652-65. PubMed ID: 17362988
    [Abstract] [Full Text] [Related]

  • 3. [Anti RS virus drugs].
    Suzumura H.
    Nihon Rinsho; 2012 Apr 04; 70(4):574-8. PubMed ID: 22568137
    [Abstract] [Full Text] [Related]

  • 4. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
    Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA.
    Pediatr Infect Dis J; 2009 Sep 04; 28(9):835-7. PubMed ID: 19636278
    [Abstract] [Full Text] [Related]

  • 5. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR.
    Expert Rev Anti Infect Ther; 2011 Jan 04; 9(1):27-32. PubMed ID: 21171875
    [Abstract] [Full Text] [Related]

  • 6. New strategies for control of respiratory syncytial virus infection.
    Nokes JD, Cane PA.
    Curr Opin Infect Dis; 2008 Dec 04; 21(6):639-43. PubMed ID: 18978532
    [Abstract] [Full Text] [Related]

  • 7. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep 04; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 8. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group.
    BMC Pediatr; 2010 Jun 03; 10():38. PubMed ID: 20525274
    [Abstract] [Full Text] [Related]

  • 9. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 03; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 10. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA, Cosgrove JF, MacMahon P.
    Ir Med J; 2000 Dec 03; 93(9):284. PubMed ID: 11209917
    [Abstract] [Full Text] [Related]

  • 11. Motavizumab for the prevention of respiratory syncytial virus infection in infants.
    Gill MA, Welliver RC.
    Expert Opin Biol Ther; 2009 Oct 03; 9(10):1335-45. PubMed ID: 19764889
    [Abstract] [Full Text] [Related]

  • 12. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R, Dooley L, Bruden D, Raelson S, Butler JC.
    Pediatr Infect Dis J; 2003 Jun 03; 22(6):540-5. PubMed ID: 12799511
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
    Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP, Motavizumab Cardiac Study Group.
    Pediatr Res; 2011 Aug 03; 70(2):186-91. PubMed ID: 21522037
    [Abstract] [Full Text] [Related]

  • 14. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T, Rozé JC, Fauroux B, French Pediatricians' Group of Sunagis Patients' Name-Based Programs.
    Pediatr Pulmonol; 2002 Sep 03; 34(3):181-8. PubMed ID: 12203846
    [Abstract] [Full Text] [Related]

  • 15. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR, Hoopes JM, Hemming VG.
    Adv Ther; 2011 Feb 03; 28(2):110-25. PubMed ID: 21318605
    [Abstract] [Full Text] [Related]

  • 16. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.
    Wu H, Pfarr DS, Losonsky GA, Kiener PA.
    Curr Top Microbiol Immunol; 2008 Feb 03; 317():103-23. PubMed ID: 17990791
    [Abstract] [Full Text] [Related]

  • 17. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
    Cardenas S, Auais A, Piedimonte G.
    Expert Rev Anti Infect Ther; 2005 Oct 03; 3(5):719-26. PubMed ID: 16207163
    [Abstract] [Full Text] [Related]

  • 18. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
    Abarca K, Jung E, Fernández P, Zhao L, Harris B, Connor EM, Losonsky GA, Motavizumab Study Group.
    Pediatr Infect Dis J; 2009 Apr 03; 28(4):267-72. PubMed ID: 19258920
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M, Respiratory Syncytial Virus (RSV) Prevention study group.
    Lancet Infect Dis; 2015 Dec 03; 15(12):1398-408. PubMed ID: 26511956
    [Abstract] [Full Text] [Related]

  • 20. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
    Winchester L, García L, García I, Concepción CB.
    P R Health Sci J; 2002 Sep 03; 21(3):191-3. PubMed ID: 12243108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.